


STOP AF First

#ESCCongress



Trial Description: Patients with paroxysmal atrial fibrillation were randomized to pulmonary vein isolation with cryoablation versus antiarrhythmic drug therapy.

($p < 0.001$)



RESULTS

- Primary efficacy endpoint, freedom from efficacy failure at 12 months, occurred in 75% of the cryoballoon ablation group vs. 45% of the antiarrhythmic drug therapy group ($p < 0.001$)
- The primary safety outcome at 12 months occurred in 1.9% of the cryoballoon ablation group vs. a performance goal of $<12\%$ ($p < 0.0001$)

CONCLUSIONS

- Among patients with paroxysmal atrial fibrillation, a first-line cryoballoon ablation strategy was superior to antiarrhythmic drug therapy
- This strategy appeared to be safe with very few procedural-related adverse events

Presented by Dr. Oussama Wazni at ESC Virtual Congress 2020